Screener
BioMarin Pharmaceuticals BMRN Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- BioMarin Pharmaceuticals (BMRN) reported finite-lived intangible assets, accumulated amortization of $594.28M in Q2 2026.
- How has BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization changed year-over-year?
- BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization increased by 23.4% year-over-year, from $481.7M to $594.28M.
- What is the long-term trend for BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization has grown at a 17.6% compound annual growth rate (CAGR), from $226.82M to $510.13M.
- What does finite-lived intangible assets, accumulated amortization mean?
- Finite-Lived Intangible Assets, Accumulated Amortization
Ask your AI about BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude